Epidemiology of HCV infection in the Central European region

Petr Urbánek¹, Pavol Kristian², Michael Makara³, Bela Hunyady⁴, Krzysztof Tomasiewicz⁵

¹Department of Internal Medicine, 1st Medical Faculty, Charles University and Central Military Hospital, Prague, Czech Republic
²Department of Infectology and Travel Medicine, Faculty of Medicine, University of P. J. Safarik, Kosice, Slovak Republic
³United Saint Istvan and Saint Laszlo Hospital, Saint Laszlo Hospital Outpatient Clinic, Budapest, Hungary
⁴Central Outpatient Clinic, Saint Laszlo Hospital, Budapest, Hungary
⁵Department of Infectious Diseases, Medical University of Lublin, Lublin, Poland

Abstract

Opinion leaders in each of four countries in the Central European region summarize the available data on hepatitis C virus (HCV) epidemiology. The overall prevalence of anti-HCV antibody reactivity in this region varies between 0.2% and 2.1%, the most prevalent HCV genotype is GT 1. The commonest route of transmission is intravenous drug abuse at present.

Key words: hepatitis C virus, prevalence.

Address for correspondence

Prof. Petr Urbánek, Department of Internal Medicine, Charles University and Central Military Hospital, 87 Ruská St., 100 00 Prague 10, Czech Republic, e-mail: petr.urbanek@uvn.cz

Introduction

Epidemiological characteristics of hepatitis C virus (HCV) infection differ significantly among different regions worldwide. This reflects many conditions including the historical context, social status, system of transfusion services and many others. On the other hand, the knowledge of epidemiological characteristics gives specialists the rational background for key decisions and recommendations, e.g. whether to perform the universal screening, how to perform such screening, which population or population subgroup is at risk and should be screened, which population should (or should not) be treated etc. This information is of particular relevance especially now, when many new highly effective but very expensive drug combinations are entering the market.

The purpose of this brief review is to provide such information and to compare epidemiological data in several Central European countries which recently established the Central European Hepatology Cooperative Group.

Czech Republic

The prevalence of anti-HCV reactivity in the general population of the Czech Republic was published in 2001 by V. Němeček [1]. They evaluated more than 3500 serum samples and found anti-HCV reactivity in 0.2%. This is the only one serological survey which has been performed up today in the Czech Republic. Chlibek et al. performed a similar study in approximately 1500 samples collected between 2013 and 2015 and they found anti-HCV reactivity in 0.4% (personal communication, unpublished data). This study was not intended as a serological survey, therefore the method of sample collection was different.

It is obligatory for the physician who diagnoses the HCV infection as the first one to report this infection to the Czech EPIDAT system. This way the EPIDAT system registers approx. 800 cases of NEWLY reported HCV infection cases annually (Table 1). Approximately 200 cases out of all reported cases every year were reported as acute – the definition may vary, this is based on the reporting physician's decision.
EPIDAT provides us also with the proportion of cases among intravenous drug users which is the only one risk factor to be reported in the system. The results are shown in Table 2.

EPIDAT does not register the HCV genotypes, so epidemiological data regarding HCV genotype are reported by investigators from large hepatological centers [2, 3]. Based on such reports we can conclude that the most prevalent HCV genotype in the Czech Republic is HCV GT 1b (80-85%) followed by HCV GT 3 (3a mostly, 10-15%).

Slovak Republic

Information about the prevalence of HCV infection in the general population in Slovakia is based on results of two larger studies. In the first study, 3,608 collected sera, within two serological surveys in the years 1997 and 2002, were tested for anti-HCV and HCV RNA. The antibody prevalence was 1.52% and HCV RNA positivity was confirmed in 0.67% [4]. More recent data are available from the EPID study, a prospective multicenter epidemiological study performed in 2010-2011. In total, 4,598 adult patients were tested with 1.41% anti-HCV prevalence and 0.70% HCV RNA positivity [5]. Similar results of both studies suggest an estimated number of 35,000 HCV infected persons in Slovakia. On the other hand, according to the Slovak National Institute of Health, only less than 4,000 HCV positive cases were reported between 1990 and 2014 in Slovakia, so most of the infected patients remain undiagnosed. The HCV genotype 1b was identified as the most common, followed by genotype 3a, other genotypes (including 1a) are rare [6].

The EPID study showed a significant difference in anti-HCV prevalence according to ALT activity. Patients with elevated ALT had a 3.8 times higher prevalence than those with normal ALT (p < 0.001), so ALT seems to be an appropriate warning sign of HCV infection [4]. Also these results underline the problem that the examination of ALT is not included into routine checkups of general practitioners in Slovakia. An additional fact related to ALT contributing to a low diagnosis rate of HCV infection is a delay of the diagnostic process. An inadequately long time, reaching 6.5 years between first time documented ALT elevation and beginning of the antiviral treatment, was observed in a cohort of 178 patients. In most cases, the underestimation of relatively low ALT values (ALT < 2 × UNL) in asymptomatic patients was the main reason for this delay [6].

In order to estimate the future epidemiologic situation, a disease progression model was designed. According to this model, HCV prevalence in Slovakia reached the maximum in the year 2005 and will decrease in the future. But the number of decompensated cirrhosis cases will rise for the next 20 years (peak around 2037), the number of HCC cases will rise for the next 25 years (peak around 2039) and a 35% increase in liver-related deaths as a result of HCV is estimated from 2013-2030 [7]. There are several strategies how to face this problem, including an increased treatment success rate by introducing new therapies and increased annual treatment rate with accepting the rational indications, but first of all it is the task to increase the diagnosis rate.

Former population-based or risk groups-based screening programs helped to improve the situation partially, however other new effective screening programs are needed. The projects cooperating with general practitioners focused on patients with elevated ALT, seem to be most promising.

In conclusion, Slovakia is a country with a relatively low prevalence of HCV infection, but the number of cases with advanced liver disease as a result of the HCV infection will increase in the next 20 years. The

| Year | HAV | HBV | HCV | HEV |
|------|-----|-----|-----|-----|
| 2005 | 322 | 361 | 844 | 37  |
| 2006 | 132 | 307 | 1022| 35  |
| 2007 | 128 | 307 | 980 | 43  |
| 2008 | 1648| 306 | 974 | 65  |
| 2009 | 1104| 247 | 836 | 99  |
| 2010 | 862 | 244 | 709 | 72  |
| 2011 | 264 | 192 | 812 | 163 |
| 2012 | 284 | 154 | 794 | 258 |
| 2013 | 348 | 133 | 873 | 218 |
| 2014 | 673 | 105 | 866 | 299 |

| Year | HCV (number of cases) |
|------|-----------------------|
| 1997 | 131                   |
| 1998 | 261                   |
| 1999 | 362                   |
| 2000 | 365                   |
| 2001 | 499                   |
| 2002 | 512                   |
| 2003 | 546                   |
| 2004 | 534                   |
| 2005 | 526                   |
| 2006 | 711                   |
| 2007 | 686                   |
| 2008 | 658                   |
estimated number of HCV-infected people in Slovakia exceeds by far the number of patients diagnosed until now, therefore efforts should be made in particular to improve screening of the infection.

Hungary

Risk factors

Only few studies examined possible risk factors. Previous surgery, having more than three pregnancies, blood transfusion and tattooing were associated with a HCV infection [8, 9]. High rates of HCV infection in the IDU population also indicate IDU as a risk factor [10], although the rates of IDU in Hungary are reportedly lower than that in other European countries [11]. A recent study showed 2.1% anti-HCV positivity among healthcare workers.

Prevalence

Limited national data are available from the National Centre for Epidemiology in Hungary.

Based on a national seroepidemiological study in 2000 by the National Centre for Epidemiology in Hungary, there were estimated 60 000-70 000 HCV cases in Hungary, which represented 0.6-0.7% of the population [10]. In 2001, a study of 477 hospital workers found a prevalence of 2.7%, indicating that occupation could be a potential risk of infection [12]. A large blood donor study in south Hungary in 2001 indicated that the prevalence of HCV in 45 719 blood donors was 0.4% [8]. Earlier blood donor studies reported slightly higher prevalence rates. One reported a prevalence of 0.73% in 15 864 blood donors [9]; another screened 9707 blood donors and found a prevalence of 0.53% [13]. Studying 120 children who received one or more blood transfusions before implementation of anti-HCV screening, a rate of 1.7% was observed [8]. Barna et al. [9] found that prevalence increased with age. Mihaly et al. [12] also reported an increased prevalence with age, from 0% in those < 21 to 9.5% in those older than 50 years. According to the Drug-Focus Point reporting system, the prevalence of HCV is increasing among people who inject drugs (PWID) [14]. This is also reflected during the screenings done in the prisons (unpublished personal data of the author).

Diagnosed incidence

The number of acute cases per 100 000 inhabitants decreased slightly from 0.4 in 2001 to 0.2 in 2005 [10, 15]. Mainly symptomatic acute HCV cases are reported via the national communicable disease reporting system [10].

Genotype

Genotypes are quite different according to the mode and time of acquiring the infection. Among the people infected before 1993 via blood and blood products, the genotype is almost exclusively 1b. In turn, the most prevalent recently infected PWIDs genotype is 1a and the remaining is about equally distributed between 3 and 1b [14].

Poland

Broad access to modern therapies has raised the need for proper assessment of HCV distribution in the population of each country. Seroprevalence of HCV in Poland was assessed in a number of studies. Results of the largest Polish study were published in 2011 by Flisiak et al. Approximately 26 000 persons were screened and anti-HCV antibodies were identified in 1.9% of individuals [16]. Next year Godzik et al. published results of screening of 4822 persons and found seropositivity in 0.95% [17]. The difference was mainly a consequence of using single step ELISA versus double step test. However, the most important findings were exactly the same: 0.6% of examined population were viremic (HCV-RNA-positive). In Flisiak study, groups of higher anti-HCV prevalence were identified. Males (2×), urban citizens (2×), people with a history of more than 3 hospital admission (2×), with blood transfusion before 1992 (3×) and intravenous drug users (7×) had been considered at higher risk of HCV infection.

These observations are in accordance with data and a general opinion that majority of chronic HCV cases are a result of blood-borne transmission, which means they were acquired in health care settings. Improvement of hygienic standards in hospitals, a low risk of vertical transmission and changes in narcotic use habits (dominance of orally administered drugs) cause a very low number of infections in infants and children. Analysis of HCV infections distribution according to age and sex shows the highest prevalence in younger males (between 30 and 60 years old) and older females (45-80 years old). These trends are similar to England and Sweden and differ from the situation in France and Spain.

In 2012 data about HCV distribution in most Polish regions were collected [18]. Genotype 1 is predominant in all regions, however the highest numbers are observed in the Western part of Poland. In North-Eastern regions, genotype 3 is present in more than 20%
of patients, whereas in central and western parts this genotype is less frequent. According to recent IFN-free therapies, this may be of great importance.

In 2014 the number of yearly registered new HCV infections exceeded 3500. It is almost 1000 more compared to previous years. In part it is a consequence of active screening campaigns, better health care providers and patients education, but also of a new case definition modified in 2014 and based on the definition accepted by the European Commission in 2012. The most important criterion is the presence of HCV-RNA or core antigen. This information shows how important methodology is for future screening strategies [19]. An increasing diagnostic rate together with broad access to modern efficient and safe therapies may only allow to control or even eradicate HCV infection.

**Conclusions**

Our brief review summarizes the currently available information on HCV epidemiology in four countries of the Central European region. It also illustrates nicely that there are significant differences not only in HCV epidemiology itself but also, and maybe more importantly, in the way of data collection which seems to be rather heterogeneous. Nevertheless, we can conclude that the overall HCV prevalence in our region is low, the most prevalent genotype is HCV 1 but the number of HCV GT 3 cases is increasing, the main route of transmission nowadays is intravenous drug abuse. Data modeling in all countries also show that HCV infection will cause significant morbidity and mortality in our countries within upcoming decades. All these facts strongly force the authors as the opinion leaders in their countries to immediately act in order to diagnose and treat more HCV infected patients.

**Disclosure**

Authors report no conflict of interest.

**References**

1. Némeček V. Sérologický přehled ČR v roce 2001 – vírová hepatitida A, B, C. Zprávy CEM 2003; 12 (příloha 1): 55-61 [Article in Czech].
2. Husa P, Husova L. Treatment of chronic hepatitis C patients with combination of alpha-interferon and ribavirin, consensus and pegylated interferons. Bratisl Lek Listy 2001; 102: 248-252.
3. Urbánek P, Husa P, Šperl J, et al. Standardní diagnostický a terapeutický postup chronické infekce virem hepatitidy C. Gastroent Hepatol 2015; 23: 455-471 [Article in Czech].
4. Schrèter I, Kristian P, Klement C, et al. Prevalence of hepatitis C virus infection in Slovakia. Klin Mikrobiol Infekc Lek 2007; 13: 54-58 [Article in Slovak].
5. Kristian P, Schrèter I, et al. EPID study, data on file.
6. Paraličová Z, Kristian P, Schrèter I. Epidemiological survey of hepatitis C at the Clinic of Infectology and Travel Medicine in Kosice. Epidemiol Mikrobiol Imunol 2009; 58: 158-162 [Article in Slovak].
7. Hatzakis A, Chulanov V, Gadano AC, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm – volume 2. J Viral Hepat 2015; 22 Suppl 1: 26-45.
8. Muller Z, Deak J, Horanyi M, et al. The detection of hepatitis C virus in South Hungary. J Clin Virol 2001; 20: 81-83.
9. Barna TK, Oszvar Z, Szendrenyi V, et al. Hepatitis C virus antibody in the serum of blood donors. Orv Hetil 1996; 137: 507-511.
10. Merkinaite S. HCV infection in Europe. Siauliu St. 5/1-21, Vilnius 01133, Lithuania: Eurasian Harm Reduction Network (EHRN), formerly Central and Eastern European Harm Reduction Network (CEEHRN), 1 October 2007.
11. European Monitoring Centre for Drugs and Drug Addiction. EMCDDA 2010 Selected Issue-Trends in Injecting Drug use in Europe European Union. Annual Report. Selected Issues/ European Monitoring Centre for Drugs and Drug Addiction. European Monitoring Centre for Drugs and Drug Addiction, 2010, p. 22.
12. Mihály I, Telegdy L, Ibrányi E, et al. Prevalence, genotype distribution and outcome of hepatitis C infections among the employees of the Hungarian Central Hospital for infectious diseases. J Hosp Infect 2001; 49: 239-244.
13. McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994; 32: 884-892.
14. Tresó B, Takács M, Dencs A, et al. Molecular epidemiology of hepatitis C virus genotypes and subtypes among injecting drug users in Hungary. Euro Surveill 2013; 18: pii=20639; doi: http://dx.doi.org/10.2807/1560-7917.ES2013.18.47.20639.
15. Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe – a review. Euro Surveill 2008; 13: 1-8.
16. Flisiak R, Halota W, Horban A, et al. Prevalence and risk factors of HCV infection in Poland. Eur J Gastroenterol Hepatol 2011; 23: 1213-1217.
17. Godzik P, Kolakowska A, Madalinski K, et al. Prevalence of anti-HCV antibodies among adults in Poland – results of cross-sectional study in general population. Przegl Epidemiol 2012; 66: 575-580 [Article in Polish].
18. Panasiuk A, Flisiak R, Mozzer-Lisewska I, et al. Distribution of HCV genotypes in Poland. Przegl Epidemiol (Epidemiol Rev) 2013; 67: 11-16 [Article in English, Polish].
19. Flisiak R, Halota W, Tomaszewicz K, et al. Forecasting the disease burden of chronic hepatitis C virus in Poland. Eur J Gastroenterol Hepatol 2015; 27: 70-76.

**Corresponding authors:**

Czech Republic

Prof. MUDr. Petr Urbánek, CSc
Department of Internal Medicine, 1st Medical Faculty, Charles University and Central Military Hospital, Prague
R.12. e-mail: petr.urbanekJuvn.cz
Slovak Republic
Doc. MUDr. Pavol Kristian, PhD
Department of Infectology and Travel Medicine,
Faculty of Medicine, University of P. J. Safarik, Kosice,
Slovak Republic
e-mail: kristian@unlp.sk

Poland
Krzysztof Tomasiewicz, MD, PhD, DSc
Department of Infectious Diseases, Medical University of Lublin,
16 Staszica St., 20-081 Lublin, Poland
e-mail: tomaskdr@poczta.fm

Hungary
Dr. Michael Makara
United Saint Istvan and Saint Laszlo Hospital,
Saint Laszlo Hospital Outpatient Clinic, Budapest, Hungary
e-mail: michael@makara.md